|Study Type:||Phase I|
|Stage:||Primary analysis complete|
|Study Start Date:||NA|
|Study Made Public:||NA|
A Phase 1 [dose escalation] safety and immunogenicity trial of an alphavirus replicon HIV-1 subtype C gag vaccine (AVX101) in healthy HIV-1 uninfected adult participants
HVTN 059 is a Phase I clinical trial to evaluate the safety and immunogenicity of alphavirus replicon HIV-1 subtype C gag vaccine, AVX101, at multiple doses.
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.